Furthermore, AMPNs degrade Pin1 expression whilepromoting PD-L1 upregulation in tumor cells, thereby triggering arobust antitumor immune response and enhancing the efficacy of PD-L1/PD-1immune checkpoint blockade therapy. The gene discussed is PIN1; the disease is neoplasm.